Overview

Indomethacin PK-PD in Extremely Preterm Neonates

Status:
Withdrawn
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
This is a phase II open-label study evaluating the pharmacokinetics and pharmacodynamics of targeted early use of indomethacin for PDA treatment in preterm neonates <27 weeks' gestational age.
Phase:
Phase 2
Details
Lead Sponsor:
University of Manitoba
Collaborators:
Health Sciences Centre, Winnipeg, Manitoba
St. Boniface General Hospital Research Centre
St. Boniface Hospital
University at Buffalo
Treatments:
Indomethacin